S
Stephanie Dufrechou
Researcher at University of Toulouse
Publications - 8
Citations - 88
Stephanie Dufrechou is an academic researcher from University of Toulouse. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 3, co-authored 5 publications receiving 26 citations.
Papers
More filters
Journal ArticleDOI
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma
Jill Corre,Aurore Perrot,Denis Caillot,Karim Belhadj,Cyrille Hulin,Xavier Leleu,Mohamad Mohty,Thierry Facon,Laure Buisson,Laura Do Souto,Romain Lannes,Stephanie Dufrechou,Naïs Prade,Frédérique Orsini-Piocelle,Laurent Voillat,Arnaud Jaccard,Lionel Karlin,Margaret Macro,Sabine Brechignac,Mamoun Dib,Laurence Sanhes,Jean Fontan,Lauriane Clement-Filliatre,Jean-Pierre Marolleau,Stephane Minvielle,Philippe Moreau,Hervé Avet-Loiseau +26 more
TL;DR: This study clearly confirms the extremely poor outcome of patients displaying "double hit", but also confirms that del(17p) alone is still a very high-risk feature, confirming its value as a prognostic indicator for poor outcome.
Journal ArticleDOI
Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia
Nicolas Duployez,Laura Jamrog,Vincent Fregona,Camille Hamelle,Laurène Fenwarth,Sophie Lejeune,Nathalie Helevaut,Sandrine Geffroy,Aurélie Caillault,Alice Marceau-Renaut,Stéphanie Poulain,Catherine Roche-Lestienne,Laetitia Largeaud,Naïs Prade,Stephanie Dufrechou,Sylvie Hébrard,Céline Berthon,Brigitte Nelken,José Fernandes,Céline Villenet,Martin Figeac,Bastien Gerby,Eric Delabesse,Claude Preudhomme,Cyril Broccardo +24 more
TL;DR: It is demonstrated that inherited genetic basis of susceptibility to BCP-ALL has been underestimated and should be considered before any familial allograft and highlighted the importance of transcriptional deregulation, particularly of genes involved in B cell differentiation in familial B CP-ALL.
Journal ArticleDOI
Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors.
Laetitia Largeaud,Emilie Bérard,Sarah Bertoli,Stephanie Dufrechou,Naïs Prade,Noémie Gadaud,Suzanne Tavitian,Pierre Bories,Isabelle Luquet,Audrey Sarry,Véronique De Mas,Françoise Huguet,Eric Delabesse,Christian Recher,Christian Recher +14 more
TL;DR: A substantial number of R/R AML patients with IDH2 mutations can be salvaged by current treatments and benefit from prolonged survival and it is expected that novel targeted agents such as enasidenib will further improve efficacy and safety in the next future.
Journal ArticleDOI
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.
Laetitia Largeaud,Pascale Cornillet-Lefebvre,Jean-François Hamel,Pierre-Yves Dumas,Naïs Prade,Stephanie Dufrechou,Julien Plenecassagnes,Isabelle Luquet,Odile Blanchet,Anne Banos,Marie C. Béné,Marc Bernard,Sarah Bertoli,Caroline Bonmati,Luc Fornecker,Romain Guieze,Lamya Haddaoui,Mathilde Hunault,Jean Christophe Ianotto,Eric Jourdan,Mario Ojeda,Pierre Peterlin,Norbert Vey,Hacene Zerazhi,Hicheri Yosr,Hicheri Yosr,Ariane Mineur,Jean-Yves Cahn,Norbert Ifrah,Christian Recher,Arnaud Pigneux,Eric Delabesse +31 more
TL;DR: This post-hoc analysis identified a subgroup of fit elderly AML patients with intermediate cytogenetics and molecular markers who may benefit from lomustine addition to intensive chemotherapy.
Journal ArticleDOI